董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| R. P. Iyer | 男 | Chief Scientific Officer and Director | 70 | 80.38万美元 | 未持股 | 2019-05-20 |
| David Arkowitz | 男 | Director | 57 | 10.63万美元 | 未持股 | 2019-05-20 |
| Kurt M. Eichler | 男 | Director | 61 | 9.92万美元 | 未持股 | 2019-05-20 |
| Timothy Clackson | 男 | Director | 53 | 13.63万美元 | 未持股 | 2019-05-20 |
| Scott Smith | 男 | Chairman of the Board | 57 | 10.03万美元 | 未持股 | 2019-05-20 |
| Todd C. Brady | 男 | Director | 47 | 9.75万美元 | 未持股 | 2019-05-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Martin Driscoll | 男 | President and Chief Executive Officer | 60 | 130.77万美元 | 未持股 | 2019-05-20 |
| R. P. Iyer | 男 | Chief Scientific Officer and Director | 70 | 80.38万美元 | 未持股 | 2019-05-20 |
| Nezam H. Afdhal | 男 | Chief Medical Officer | 62 | 89.62万美元 | 未持股 | 2019-05-20 |
| Jonathan Freve | 男 | Chief Financial Officer and Treasurer | 41 | 49.19万美元 | 未持股 | 2019-05-20 |
董事简历
中英对照 | 中文 | 英文- R. P. Iyer
-
R. P. Iyer，是我们的创始人；本公司2002年创立起，担任我们的首席科学官和董事会成员。是临床阶段生物技术公司-Origenix Technologies, Inc.的联合创始人，1998-2002年担任发现副总裁。1993-1998，他在Hybridon, Inc. （现为Idera Pharmaceuticals, Inc.）的发现集团担任高级科学家和副总监。此前，他曾是Bombay大学的药物化学教授，德州大学M. D. Anderson Cancer Center 的客座科学家，以及FDA/NIH生物制品评价和研究中心的客座科学家。他持有化学和物理荣誉学士学位，医药技术和精细化工学士学位，以及Bombay大学药用和医药化学硕士学位。持有加州Stockton市Pacific 大学的医药科学博士学位，以及在Johns Hopkins大学Oak Ridge National 实验室进行博士后学习。
R. P. Iyer is one of our founders and has been our Chief Scientific Officer and a member of our Board of Directors since our inception in 2002. Dr. Iyer was co-founder and VP of Discovery at Origenix Technologies, Inc., a clinical-stage biotech company, from 1998 to 2002. From 1993 to 1998 Dr. Iyer was a Senior Scientist and Associate Director of the Discovery Group at Hybridon, Inc. now known as Idera Pharmaceuticals, Inc.. Previously, Dr. Iyer was a Professor of Medicinal Chemistry at the University of Bombay, a Visiting Scientist at the University of Texas, M. D. Anderson Cancer Center and a Visiting Scientist at the Center for Biologics Evaluation and Research at FDA/NIH. Dr. Iyer received his BS, with honors, in chemistry and physics, his BS degrees in the Technology of Pharmaceuticals and Fine Chemicals and his MS in Medicinal and Pharmaceutical Chemistry from the University of Bombay. He received a Ph.D. degree in Pharmaceutical Sciences from the University of the Pacific in Stockton, California and carried out postdoctoral work at the Oak Ridge National Laboratory and at Johns Hopkins University. - R. P. Iyer，是我们的创始人；本公司2002年创立起，担任我们的首席科学官和董事会成员。是临床阶段生物技术公司-Origenix Technologies, Inc.的联合创始人，1998-2002年担任发现副总裁。1993-1998，他在Hybridon, Inc. （现为Idera Pharmaceuticals, Inc.）的发现集团担任高级科学家和副总监。此前，他曾是Bombay大学的药物化学教授，德州大学M. D. Anderson Cancer Center 的客座科学家，以及FDA/NIH生物制品评价和研究中心的客座科学家。他持有化学和物理荣誉学士学位，医药技术和精细化工学士学位，以及Bombay大学药用和医药化学硕士学位。持有加州Stockton市Pacific 大学的医药科学博士学位，以及在Johns Hopkins大学Oak Ridge National 实验室进行博士后学习。
- R. P. Iyer is one of our founders and has been our Chief Scientific Officer and a member of our Board of Directors since our inception in 2002. Dr. Iyer was co-founder and VP of Discovery at Origenix Technologies, Inc., a clinical-stage biotech company, from 1998 to 2002. From 1993 to 1998 Dr. Iyer was a Senior Scientist and Associate Director of the Discovery Group at Hybridon, Inc. now known as Idera Pharmaceuticals, Inc.. Previously, Dr. Iyer was a Professor of Medicinal Chemistry at the University of Bombay, a Visiting Scientist at the University of Texas, M. D. Anderson Cancer Center and a Visiting Scientist at the Center for Biologics Evaluation and Research at FDA/NIH. Dr. Iyer received his BS, with honors, in chemistry and physics, his BS degrees in the Technology of Pharmaceuticals and Fine Chemicals and his MS in Medicinal and Pharmaceutical Chemistry from the University of Bombay. He received a Ph.D. degree in Pharmaceutical Sciences from the University of the Pacific in Stockton, California and carried out postdoctoral work at the Oak Ridge National Laboratory and at Johns Hopkins University.
- David Arkowitz
-
David Arkowitz，2014年2月起担任董事会成员。2013年起在生物技术公司Visterra, Inc.担任首席运营官和财务总监。此前，2011年6月-2013年9月，在 Mascoma Corporation（该公司被一家生物转化公司- Lallemand, Inc.收购）担任财务总监和总经理。2007年4月-2011年5月，在一家专业医药公司-AMAG Pharmaceuticals，担任执行副总裁、财务总监和首席商务官。此前，他曾担任Idenix Pharmaceuticals, Inc.（被生物医药公司Merck & Co.，收购）的财务总监和司库。在职业生涯的早期，他曾在 Merck & Co。 工作了超过13年，包括U.S. Human Health副总裁和总会计师，以及全球研发部总会计师。2007-2009，在Aegerion Pharmaceuticals, Inc.，以及2005-2009在 ImpactRx Inc. 董事会任职。他持有Brandeis 大学的数学学士学位和Columbia 大学商学院的财务专业工商管理硕士学位。
David Arkowitz has been a member of our Board of Directors since January 2014. Since May 2018 Mr. Arkowitz has served as the Chief Financial Officer and Treasurer of Flexion Therapeutics, Inc., a biotechnology company. Prior to that, Mr. Arkowitz served as Chief Operating Officer and Chief Financial Officer of Visterra, Inc., which was acquired by Otsuka Pharmaceutical Co., Ltd., a biotechnology company, from September 2013 to May 2018. Prior to joining Visterra, he served as Chief Financial Officer and General Manager at Mascoma Corporation, which was acquired by Lallemand, Inc., a bioconversion company, from 2011 to 2013. From 2007 to 2011 Mr. Arkowitz was Executive Vice President, Chief Financial Officer and Chief Business Officer of AMAG Pharmaceuticals, a specialty pharmaceutical company. Prior to his tenure at AMAG, he served as Chief Financial Officer and Treasurer of Idenix Pharmaceuticals, Inc., which was acquired by Merck & Co., a biopharmaceutical company. Earlier in his career, he spent more than thirteen years at Merck & Co. including as Vice President and Controller of the U.S. Human Health division and as Controller of the Global Research and Development division. Mr. Arkowitz currently serves on the board of directors of Proteostasis Therapeutics, Inc., a publicly traded biotechnology company, and previously served on the board of directors of Aegerion Pharmaceuticals, Inc., also a publicly traded biotechnology company. Mr. Arkowitz has a BA in Mathematics from Brandeis University and an MBA in Finance from Columbia University Business School. - David Arkowitz，2014年2月起担任董事会成员。2013年起在生物技术公司Visterra, Inc.担任首席运营官和财务总监。此前，2011年6月-2013年9月，在 Mascoma Corporation（该公司被一家生物转化公司- Lallemand, Inc.收购）担任财务总监和总经理。2007年4月-2011年5月，在一家专业医药公司-AMAG Pharmaceuticals，担任执行副总裁、财务总监和首席商务官。此前，他曾担任Idenix Pharmaceuticals, Inc.（被生物医药公司Merck & Co.，收购）的财务总监和司库。在职业生涯的早期，他曾在 Merck & Co。 工作了超过13年，包括U.S. Human Health副总裁和总会计师，以及全球研发部总会计师。2007-2009，在Aegerion Pharmaceuticals, Inc.，以及2005-2009在 ImpactRx Inc. 董事会任职。他持有Brandeis 大学的数学学士学位和Columbia 大学商学院的财务专业工商管理硕士学位。
- David Arkowitz has been a member of our Board of Directors since January 2014. Since May 2018 Mr. Arkowitz has served as the Chief Financial Officer and Treasurer of Flexion Therapeutics, Inc., a biotechnology company. Prior to that, Mr. Arkowitz served as Chief Operating Officer and Chief Financial Officer of Visterra, Inc., which was acquired by Otsuka Pharmaceutical Co., Ltd., a biotechnology company, from September 2013 to May 2018. Prior to joining Visterra, he served as Chief Financial Officer and General Manager at Mascoma Corporation, which was acquired by Lallemand, Inc., a bioconversion company, from 2011 to 2013. From 2007 to 2011 Mr. Arkowitz was Executive Vice President, Chief Financial Officer and Chief Business Officer of AMAG Pharmaceuticals, a specialty pharmaceutical company. Prior to his tenure at AMAG, he served as Chief Financial Officer and Treasurer of Idenix Pharmaceuticals, Inc., which was acquired by Merck & Co., a biopharmaceutical company. Earlier in his career, he spent more than thirteen years at Merck & Co. including as Vice President and Controller of the U.S. Human Health division and as Controller of the Global Research and Development division. Mr. Arkowitz currently serves on the board of directors of Proteostasis Therapeutics, Inc., a publicly traded biotechnology company, and previously served on the board of directors of Aegerion Pharmaceuticals, Inc., also a publicly traded biotechnology company. Mr. Arkowitz has a BA in Mathematics from Brandeis University and an MBA in Finance from Columbia University Business School.
- Kurt M. Eichler
-
Kurt M. Eichler ，2015年7月起担任董事会成员。2013年10月从 LCOR, Inc. 退休起，他一直在自己的数个房地产相关投资和发展公司工作。1982年一直到2013年退休前，在LCOR担任数个管理和行政职位；最近担任执行副总裁和总负责人。1979-1982，他在Merrill Lynch Hubbard Inc.房地产债务和股权融资集团工作。此前，在两个私有初创企业-Dara Biosciences, Inc. 和MiMedx Group, Inc.董事会任职，目前在 Maia Yogurt董事会任职。持有Wyoming大学的工商管理学士学位。
Kurt M. Eichler has been a member of our Board of Directors since July 2015. Since his retirement from LCOR, Inc., a private real estate investment and development company specializing in complex urban development, in October 2013 Mr. Eichler has been self-employed in several real estate related investment and development ventures. Mr. Eichler worked in several management and executive capacities at LCOR from 1982 through his retirement in 2013 after serving as a Principal most recently as Executive Vice President and Principal. From 1979 to 1982 Mr. Eichler worked at Merrill Lynch Hubbard Inc. in the Real Estate Debt and Equity Finance Group. Mr. Eichler previously served on the board of directors of two public companies, Dara Biosciences, Inc. and MiMedx Group, Inc. Mr. Eichler holds a BS in Business Administration from the University of Wyoming. - Kurt M. Eichler ，2015年7月起担任董事会成员。2013年10月从 LCOR, Inc. 退休起，他一直在自己的数个房地产相关投资和发展公司工作。1982年一直到2013年退休前，在LCOR担任数个管理和行政职位；最近担任执行副总裁和总负责人。1979-1982，他在Merrill Lynch Hubbard Inc.房地产债务和股权融资集团工作。此前，在两个私有初创企业-Dara Biosciences, Inc. 和MiMedx Group, Inc.董事会任职，目前在 Maia Yogurt董事会任职。持有Wyoming大学的工商管理学士学位。
- Kurt M. Eichler has been a member of our Board of Directors since July 2015. Since his retirement from LCOR, Inc., a private real estate investment and development company specializing in complex urban development, in October 2013 Mr. Eichler has been self-employed in several real estate related investment and development ventures. Mr. Eichler worked in several management and executive capacities at LCOR from 1982 through his retirement in 2013 after serving as a Principal most recently as Executive Vice President and Principal. From 1979 to 1982 Mr. Eichler worked at Merrill Lynch Hubbard Inc. in the Real Estate Debt and Equity Finance Group. Mr. Eichler previously served on the board of directors of two public companies, Dara Biosciences, Inc. and MiMedx Group, Inc. Mr. Eichler holds a BS in Business Administration from the University of Wyoming.
- Timothy Clackson
-
Timothy Clackson自2018年3月以来一直是我们的董事会成员。从2018年5月至今，Clackson博士担任Akrevia Therapeutics（一家私人交易的生物技术公司）研究与开发的总裁兼执行Vice President。从2010年6月到2017年5月，Clackson博士担任ARIADPharmaceuticals，Inc.的研究与开发总裁，直到该公司被武田收购。在此之前，Clackson博士担任Ariad&；8217；S的高级副总裁和首席科学官。1991年至1994年，Clackson博士是Genentech，Inc.的博士后，1994年12月加入ARIADPharmaceuticals，Inc.。Clackson博士目前在MassBio和两家私人交易的生物技术公司的董事会任职。他在牛津大学（University of Oxford）获得生物化学学士学位，在剑桥大学（University of Cambridge）获得生物学博士学位。
Timothy Clackson has been a member of our Board of Directors since March 2018. From May 2018 to present, Dr. Clackson has served as President and Executive Vice President of Research and Development of Akrevia Therapeutics, a privately traded biotechnology company. From June 2010 to May 2017 Dr. Clackson served as president of research and development at ARIAD Pharmaceuticals, Inc. until its acquisition by Takeda. Prior to that, Dr. Clackson served as ARIAD’s senior vice president and chief scientific officer. Dr. Clackson was a postdoctoral fellow at Genentech, Inc. from 1991 to 1994 prior to his joining ARIAD Pharmaceuticals, Inc. in December 1994. Dr. Clackson currently serves on the board of directors of MassBio and two privately traded biotechnology companies. He received a B.A. in biochemistry from the University of Oxford, and a Ph.D. in biology from the University of Cambridge. - Timothy Clackson自2018年3月以来一直是我们的董事会成员。从2018年5月至今，Clackson博士担任Akrevia Therapeutics（一家私人交易的生物技术公司）研究与开发的总裁兼执行Vice President。从2010年6月到2017年5月，Clackson博士担任ARIADPharmaceuticals，Inc.的研究与开发总裁，直到该公司被武田收购。在此之前，Clackson博士担任Ariad&；8217；S的高级副总裁和首席科学官。1991年至1994年，Clackson博士是Genentech，Inc.的博士后，1994年12月加入ARIADPharmaceuticals，Inc.。Clackson博士目前在MassBio和两家私人交易的生物技术公司的董事会任职。他在牛津大学（University of Oxford）获得生物化学学士学位，在剑桥大学（University of Cambridge）获得生物学博士学位。
- Timothy Clackson has been a member of our Board of Directors since March 2018. From May 2018 to present, Dr. Clackson has served as President and Executive Vice President of Research and Development of Akrevia Therapeutics, a privately traded biotechnology company. From June 2010 to May 2017 Dr. Clackson served as president of research and development at ARIAD Pharmaceuticals, Inc. until its acquisition by Takeda. Prior to that, Dr. Clackson served as ARIAD’s senior vice president and chief scientific officer. Dr. Clackson was a postdoctoral fellow at Genentech, Inc. from 1991 to 1994 prior to his joining ARIAD Pharmaceuticals, Inc. in December 1994. Dr. Clackson currently serves on the board of directors of MassBio and two privately traded biotechnology companies. He received a B.A. in biochemistry from the University of Oxford, and a Ph.D. in biology from the University of Cambridge.
- Scott Smith
-
Scott Smith自2018年9月起担任BioAtla公司总裁。在他在全球生物制药公司Celgene的10年任职期间，从2008年9月到2018年4月，他的领导角色从全球炎症和免疫疾病市场副总裁扩展到该部门的全球负责人，再到炎症和免疫疾病特许经营总裁，最终于2017年被任命为Celgene的总裁兼首席运营官。作为一个对免疫学特别关注的人，Smith先生推动了Celgene的炎症和免疫疾病部门从全球13人增长到1300多人，并监督了千亿级药品Otezla的临床开发、全球注册和商业成功。Smith先生在制药公司Pharmacia担任各种职位，从1987年8月一直到它于2003年被Pfizer收购。他还在Biovail担任各种职位，包括加拿大总经理、美国总经理和全球商业运营副总裁和负责人等，从2003年7月到2008年8月，他负责销售和营销，制定和执行商业和业务拓展战略，并为监管和临床开发战略做出贡献。Smith先生还担任Titan Pharmaceuticals、Triumvira Immunologics和Spring Bank Pharmaceuticals的董事会成员。Smith先生在the University of Western Ontario获得化学和生物学的学士学位，以及药理学和毒理学的高级学士学位，还在Thunderbird School of Global Management获得国际商业管理硕士学位。
Scott Smith,Chief Executive Officer (since April 2023), Viatris;President (2018-2023), BioAtla, Inc. (NASDAQ: BCAB) ("BioAtla"), a global biotechnology company focused on the development of Conditionally Active Biologics antibody therapeutics.Served as an executive (2008-2018), rising up the ranks from SVP and Global Head of Immunology to President of Inflammation and Immunology and then, beginning in 2017, President and Chief Operating Officer, Celgene Corporation, a global biopharmaceutical company.Public Company Management, Corporate Governance, Global Business, Healthcare Industry, Risk Oversight/Compliance, and Strategy and M&A Experience acquired during his more than 35 years in the healthcare industry, which has resulted in him possessing vast global commercial and pharmaceutical expertise and a proven ability to build, grow and manage large complex organizations utilizing his substantial experience in developing and executing regulatory, clinical, and business development strategies as displayed by time at BioAtla, where he built a clinical development structure that moved multiple assets from investigational new drug applications into late stage clinical development, drove the company's long-term strategic operational plan and led all business development activities and, prior to that, his time at Celgene where he led the company's oncology, inflammation and immunology franchise, commercial operations and clinical development. - Scott Smith自2018年9月起担任BioAtla公司总裁。在他在全球生物制药公司Celgene的10年任职期间，从2008年9月到2018年4月，他的领导角色从全球炎症和免疫疾病市场副总裁扩展到该部门的全球负责人，再到炎症和免疫疾病特许经营总裁，最终于2017年被任命为Celgene的总裁兼首席运营官。作为一个对免疫学特别关注的人，Smith先生推动了Celgene的炎症和免疫疾病部门从全球13人增长到1300多人，并监督了千亿级药品Otezla的临床开发、全球注册和商业成功。Smith先生在制药公司Pharmacia担任各种职位，从1987年8月一直到它于2003年被Pfizer收购。他还在Biovail担任各种职位，包括加拿大总经理、美国总经理和全球商业运营副总裁和负责人等，从2003年7月到2008年8月，他负责销售和营销，制定和执行商业和业务拓展战略，并为监管和临床开发战略做出贡献。Smith先生还担任Titan Pharmaceuticals、Triumvira Immunologics和Spring Bank Pharmaceuticals的董事会成员。Smith先生在the University of Western Ontario获得化学和生物学的学士学位，以及药理学和毒理学的高级学士学位，还在Thunderbird School of Global Management获得国际商业管理硕士学位。
- Scott Smith,Chief Executive Officer (since April 2023), Viatris;President (2018-2023), BioAtla, Inc. (NASDAQ: BCAB) ("BioAtla"), a global biotechnology company focused on the development of Conditionally Active Biologics antibody therapeutics.Served as an executive (2008-2018), rising up the ranks from SVP and Global Head of Immunology to President of Inflammation and Immunology and then, beginning in 2017, President and Chief Operating Officer, Celgene Corporation, a global biopharmaceutical company.Public Company Management, Corporate Governance, Global Business, Healthcare Industry, Risk Oversight/Compliance, and Strategy and M&A Experience acquired during his more than 35 years in the healthcare industry, which has resulted in him possessing vast global commercial and pharmaceutical expertise and a proven ability to build, grow and manage large complex organizations utilizing his substantial experience in developing and executing regulatory, clinical, and business development strategies as displayed by time at BioAtla, where he built a clinical development structure that moved multiple assets from investigational new drug applications into late stage clinical development, drove the company's long-term strategic operational plan and led all business development activities and, prior to that, his time at Celgene where he led the company's oncology, inflammation and immunology franchise, commercial operations and clinical development.
- Todd C. Brady
-
Todd C. Brady自2012年1月起担任Aldeyra Therapeutics，Inc.总裁兼首席执行官，自2005年起成为Aldeyla Therapeunics，Inc.董事会成员。加入Aldeyra之前，他曾担任Domain Associates, LLC（一家领先的医疗风险投资公司）的常驻企业家，从2004年到2013年担任负责人。他目前担任Evoke Pharma, Inc.（一家公开交易的医疗保健公司）的董事会成员。他持有Duke University研究生院的病理学博士学位，Duke University医学院的医学博士学位，以及Dartmouth College的哲学和心理学学士学位。
Todd C. Brady,has served as Aldeyra Therapeutics, Inc. President and Chief Executive Officer since January of 2012 and as a member of Aldeyra Therapeutics, Inc. Board since 2005. Prior to Aldeyra, Dr. Brady served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the board of directors of Evoke Pharma, Inc., a publicly traded healthcare company. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, a M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology. - Todd C. Brady自2012年1月起担任Aldeyra Therapeutics，Inc.总裁兼首席执行官，自2005年起成为Aldeyla Therapeunics，Inc.董事会成员。加入Aldeyra之前，他曾担任Domain Associates, LLC（一家领先的医疗风险投资公司）的常驻企业家，从2004年到2013年担任负责人。他目前担任Evoke Pharma, Inc.（一家公开交易的医疗保健公司）的董事会成员。他持有Duke University研究生院的病理学博士学位，Duke University医学院的医学博士学位，以及Dartmouth College的哲学和心理学学士学位。
- Todd C. Brady,has served as Aldeyra Therapeutics, Inc. President and Chief Executive Officer since January of 2012 and as a member of Aldeyra Therapeutics, Inc. Board since 2005. Prior to Aldeyra, Dr. Brady served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the board of directors of Evoke Pharma, Inc., a publicly traded healthcare company. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, a M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology.
高管简历
中英对照 | 中文 | 英文- Martin Driscoll
Martin Driscoll，2015年8月起担任我们总裁、首席执行官和董事；2015年9月被任命为董事长。2010年10月-2015年7月，在风险支持的临床阶段生物医药公司（2015年7月被加拿大一家私有生命科学公司收购）- Asmacure Ltée担任首席执行官。2008年3月-2010年7月，他在一家于2010年7月被Hospira, Inc.收购的上市急性疼痛护理产品开发商-Javelin Pharmaceuticals, Inc.担任首席执行官。此前，他曾在Schering-Plough Corporation, ViroPharma, Inc.和Reliant Pharmaceuticals, Inc.担任数个高级管理职位。2007年，联合创立了一家女士护理产品私有企业-Pear Tree Pharmaceuticals, Inc.。他目前在上市公司MetaStat, Inc.和私有企业Asmacure Inc.董事会任职，此前在两家上市公司- Javelin Pharmaceuticals, Inc.和Genta, Inc.董事会任职；以及在两家私有企业-Asmacure Ltée和Pear Tree Pharmaceuticals, Inc. 董事会任职。持有德州大学奥斯丁分校的通信学士学位。
Martin Driscoll has been our President, Chief Executive Officer and Director since August 2015. In September 2015 Mr. Driscoll was appointed Chairman of our Board of Directors, a position he held until Mr. Smith’s appointment to that position on January 1 2019. From October 2010 until July 2015 he served as CEO of Asmacure Ltée, a venture-backed clinical-stage biopharmaceutical company, which was acquired by a privately held Canadian life sciences company in July 2015. Prior to Asmacure, from 2008 until 2010 Mr. Driscoll was the Chief Executive Officer and a director of Javelin Pharmaceuticals, Inc., a publicly traded developer of acute care pain products that was acquired in 2010 by Hospira, Inc. Prior to that, he served in various senior management roles at Schering-Plough Corporation, ViroPharma, Inc. and Reliant Pharmaceuticals, Inc. In 2007 Mr. Driscoll co-founded Pear Tree Pharmaceuticals, Inc., a privately held developer of women’s healthcare products. Mr. Driscoll does not currently serve on the board of directors of any publicly traded company, but he previously served on the board of directors of Javelin Pharmaceuticals, Inc., Genta, Inc. and MetaStat, Inc., all of which are or were publicly traded biotechnology companies. Mr. Driscoll holds a B.Sc. in communications from the University of Texas at Austin.- Martin Driscoll，2015年8月起担任我们总裁、首席执行官和董事；2015年9月被任命为董事长。2010年10月-2015年7月，在风险支持的临床阶段生物医药公司（2015年7月被加拿大一家私有生命科学公司收购）- Asmacure Ltée担任首席执行官。2008年3月-2010年7月，他在一家于2010年7月被Hospira, Inc.收购的上市急性疼痛护理产品开发商-Javelin Pharmaceuticals, Inc.担任首席执行官。此前，他曾在Schering-Plough Corporation, ViroPharma, Inc.和Reliant Pharmaceuticals, Inc.担任数个高级管理职位。2007年，联合创立了一家女士护理产品私有企业-Pear Tree Pharmaceuticals, Inc.。他目前在上市公司MetaStat, Inc.和私有企业Asmacure Inc.董事会任职，此前在两家上市公司- Javelin Pharmaceuticals, Inc.和Genta, Inc.董事会任职；以及在两家私有企业-Asmacure Ltée和Pear Tree Pharmaceuticals, Inc. 董事会任职。持有德州大学奥斯丁分校的通信学士学位。
- Martin Driscoll has been our President, Chief Executive Officer and Director since August 2015. In September 2015 Mr. Driscoll was appointed Chairman of our Board of Directors, a position he held until Mr. Smith’s appointment to that position on January 1 2019. From October 2010 until July 2015 he served as CEO of Asmacure Ltée, a venture-backed clinical-stage biopharmaceutical company, which was acquired by a privately held Canadian life sciences company in July 2015. Prior to Asmacure, from 2008 until 2010 Mr. Driscoll was the Chief Executive Officer and a director of Javelin Pharmaceuticals, Inc., a publicly traded developer of acute care pain products that was acquired in 2010 by Hospira, Inc. Prior to that, he served in various senior management roles at Schering-Plough Corporation, ViroPharma, Inc. and Reliant Pharmaceuticals, Inc. In 2007 Mr. Driscoll co-founded Pear Tree Pharmaceuticals, Inc., a privately held developer of women’s healthcare products. Mr. Driscoll does not currently serve on the board of directors of any publicly traded company, but he previously served on the board of directors of Javelin Pharmaceuticals, Inc., Genta, Inc. and MetaStat, Inc., all of which are or were publicly traded biotechnology companies. Mr. Driscoll holds a B.Sc. in communications from the University of Texas at Austin.
- R. P. Iyer
R. P. Iyer，是我们的创始人；本公司2002年创立起，担任我们的首席科学官和董事会成员。是临床阶段生物技术公司-Origenix Technologies, Inc.的联合创始人，1998-2002年担任发现副总裁。1993-1998，他在Hybridon, Inc. （现为Idera Pharmaceuticals, Inc.）的发现集团担任高级科学家和副总监。此前，他曾是Bombay大学的药物化学教授，德州大学M. D. Anderson Cancer Center 的客座科学家，以及FDA/NIH生物制品评价和研究中心的客座科学家。他持有化学和物理荣誉学士学位，医药技术和精细化工学士学位，以及Bombay大学药用和医药化学硕士学位。持有加州Stockton市Pacific 大学的医药科学博士学位，以及在Johns Hopkins大学Oak Ridge National 实验室进行博士后学习。
R. P. Iyer is one of our founders and has been our Chief Scientific Officer and a member of our Board of Directors since our inception in 2002. Dr. Iyer was co-founder and VP of Discovery at Origenix Technologies, Inc., a clinical-stage biotech company, from 1998 to 2002. From 1993 to 1998 Dr. Iyer was a Senior Scientist and Associate Director of the Discovery Group at Hybridon, Inc. now known as Idera Pharmaceuticals, Inc.. Previously, Dr. Iyer was a Professor of Medicinal Chemistry at the University of Bombay, a Visiting Scientist at the University of Texas, M. D. Anderson Cancer Center and a Visiting Scientist at the Center for Biologics Evaluation and Research at FDA/NIH. Dr. Iyer received his BS, with honors, in chemistry and physics, his BS degrees in the Technology of Pharmaceuticals and Fine Chemicals and his MS in Medicinal and Pharmaceutical Chemistry from the University of Bombay. He received a Ph.D. degree in Pharmaceutical Sciences from the University of the Pacific in Stockton, California and carried out postdoctoral work at the Oak Ridge National Laboratory and at Johns Hopkins University.- R. P. Iyer，是我们的创始人；本公司2002年创立起，担任我们的首席科学官和董事会成员。是临床阶段生物技术公司-Origenix Technologies, Inc.的联合创始人，1998-2002年担任发现副总裁。1993-1998，他在Hybridon, Inc. （现为Idera Pharmaceuticals, Inc.）的发现集团担任高级科学家和副总监。此前，他曾是Bombay大学的药物化学教授，德州大学M. D. Anderson Cancer Center 的客座科学家，以及FDA/NIH生物制品评价和研究中心的客座科学家。他持有化学和物理荣誉学士学位，医药技术和精细化工学士学位，以及Bombay大学药用和医药化学硕士学位。持有加州Stockton市Pacific 大学的医药科学博士学位，以及在Johns Hopkins大学Oak Ridge National 实验室进行博士后学习。
- R. P. Iyer is one of our founders and has been our Chief Scientific Officer and a member of our Board of Directors since our inception in 2002. Dr. Iyer was co-founder and VP of Discovery at Origenix Technologies, Inc., a clinical-stage biotech company, from 1998 to 2002. From 1993 to 1998 Dr. Iyer was a Senior Scientist and Associate Director of the Discovery Group at Hybridon, Inc. now known as Idera Pharmaceuticals, Inc.. Previously, Dr. Iyer was a Professor of Medicinal Chemistry at the University of Bombay, a Visiting Scientist at the University of Texas, M. D. Anderson Cancer Center and a Visiting Scientist at the Center for Biologics Evaluation and Research at FDA/NIH. Dr. Iyer received his BS, with honors, in chemistry and physics, his BS degrees in the Technology of Pharmaceuticals and Fine Chemicals and his MS in Medicinal and Pharmaceutical Chemistry from the University of Bombay. He received a Ph.D. degree in Pharmaceutical Sciences from the University of the Pacific in Stockton, California and carried out postdoctoral work at the Oak Ridge National Laboratory and at Johns Hopkins University.
- Nezam H. Afdhal
Nezam H. Afdhal，2015年11月起担任我们首席医疗官；2011年初-2015年11月，担任我们顾问。Afdhal 博士从2015年1月起在Beth Israel Deaconess Medical Center担任肝病高级医师；2000年1月-2014年12月担任肝病主任。2000年起在哈佛医学院担任医学教授。目前还在多个医药公司科学顾问委员会任职，包括：Gilead Sciences, Inc., GlaxoSmithKline Plc, Bristol Myers Squibb Company和Novartis Pharmaceuticals。他于1981年从以色列Royal College of Surgeons获得他的学士学位；在Dublin大学学院和Boston 大学医学院完成他的研究。
Nezam H. Afdhal has been our Chief Medical Officer since November 2015 and served as a consultant to us from early 2011 to November 2015. Dr. Afdhal has also served as a Senior Physician in Hepatology at the Beth Israel Deaconess Medical Center since January 2015 and served as Chief of Hepatology from January 2000 to December 2014. Dr. Afdhal has also served as a Professor of Medicine at Harvard Medical School since 2000. Dr. Afdhal serves on the scientific advisory board of Gilead Sciences,Inc. Dr. Afdhal received his M.B. B.Ch. degree in 1981 from the Royal College of Surgeons in Ireland and did fellowship training at University College in Dublin and at Boston University School of Medicine.- Nezam H. Afdhal，2015年11月起担任我们首席医疗官；2011年初-2015年11月，担任我们顾问。Afdhal 博士从2015年1月起在Beth Israel Deaconess Medical Center担任肝病高级医师；2000年1月-2014年12月担任肝病主任。2000年起在哈佛医学院担任医学教授。目前还在多个医药公司科学顾问委员会任职，包括：Gilead Sciences, Inc., GlaxoSmithKline Plc, Bristol Myers Squibb Company和Novartis Pharmaceuticals。他于1981年从以色列Royal College of Surgeons获得他的学士学位；在Dublin大学学院和Boston 大学医学院完成他的研究。
- Nezam H. Afdhal has been our Chief Medical Officer since November 2015 and served as a consultant to us from early 2011 to November 2015. Dr. Afdhal has also served as a Senior Physician in Hepatology at the Beth Israel Deaconess Medical Center since January 2015 and served as Chief of Hepatology from January 2000 to December 2014. Dr. Afdhal has also served as a Professor of Medicine at Harvard Medical School since 2000. Dr. Afdhal serves on the scientific advisory board of Gilead Sciences,Inc. Dr. Afdhal received his M.B. B.Ch. degree in 1981 from the Royal College of Surgeons in Ireland and did fellowship training at University College in Dublin and at Boston University School of Medicine.
- Jonathan Freve
Jonathan Freve，2015年1月起担任我们财务总监、司库和秘书。2014年3月-2014年11月，担任Santaris Pharma A/S的高级财务总监，该公司被生物技术公司 F. Hoffmann-LaRoche Ltd.收购。此前，他于2011年4月-2014年3月期间，在一家拥有、运营和开发回收利用能源生产设备的公司-Brookfield Renewable Energy Partners, L.P。担任总会计师。2007年10月-2011年4月，在信息技术咨询公司Virtusa Corporation担任总会计师。他在FASB和PricewaterhouseCoopers（在那从事审计和交易服务业务）开始他的职业生涯。他是Commonwealth of Massachusetts的一名注册会计师；持有Massachusetts Amherst大学的会计工商管理学士学位。
Jonathan Freve has served as our Chief Financial Officer since 2020. Prior to joining us, Mr. Freve served as Chief Financial Officer and Treasurer of Spring Bank Pharmaceuticals, Inc., a Delaware biopharmaceutical company, from December 2014 to April 2020. Prior to joining Spring Bank, Mr. Freve worked at Santaris Pharma, a Danish biotechnology company, as Sr. Director of Finance from February 2014 to November 2014. Earlier in his career, Mr. Freve worked at the FASB and at PricewaterhouseCoopers LLC, where he worked in audit and transaction services. Mr. Freve holds a B.A. in Business Administration from the University of Massachusetts Amherst.- Jonathan Freve，2015年1月起担任我们财务总监、司库和秘书。2014年3月-2014年11月，担任Santaris Pharma A/S的高级财务总监，该公司被生物技术公司 F. Hoffmann-LaRoche Ltd.收购。此前，他于2011年4月-2014年3月期间，在一家拥有、运营和开发回收利用能源生产设备的公司-Brookfield Renewable Energy Partners, L.P。担任总会计师。2007年10月-2011年4月，在信息技术咨询公司Virtusa Corporation担任总会计师。他在FASB和PricewaterhouseCoopers（在那从事审计和交易服务业务）开始他的职业生涯。他是Commonwealth of Massachusetts的一名注册会计师；持有Massachusetts Amherst大学的会计工商管理学士学位。
- Jonathan Freve has served as our Chief Financial Officer since 2020. Prior to joining us, Mr. Freve served as Chief Financial Officer and Treasurer of Spring Bank Pharmaceuticals, Inc., a Delaware biopharmaceutical company, from December 2014 to April 2020. Prior to joining Spring Bank, Mr. Freve worked at Santaris Pharma, a Danish biotechnology company, as Sr. Director of Finance from February 2014 to November 2014. Earlier in his career, Mr. Freve worked at the FASB and at PricewaterhouseCoopers LLC, where he worked in audit and transaction services. Mr. Freve holds a B.A. in Business Administration from the University of Massachusetts Amherst.